The FDA launched an expedited investigational new drug (IND) pilot program intended to reduce time spent in early submissions and to apply more risk-proportionate, phase-appropriate judgment during IND development. The initiative is part of the broader U.S. effort to onshore clinical trials through HHS. Industry and trial-operations experts described the goal as shortening sequential steps in submission preparation while keeping FDA review standards and timelines unchanged. The pilot is tied to the administration’s push for earlier first-patient dosing in the U.S. compared with jurisdictions where development and site activation can move faster. The rollout also arrives alongside other FDA initiatives such as PreCheck for manufacturing-site feedback, reflecting a continued focus on reducing administrative friction rather than changing underlying evidentiary requirements.